Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation

Tianjin First Central Hospital

Status: Unknown

Conditions: Evidence of Liver Transplantation; Myocardial Injury

Treatments: Drug: Normal saline; Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT03013634

TianjinFCH

Details and patient eligibility

About

The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation

Full description

Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• End stage liver disease scheduled for liver transplantation in Tianjin First Center Hospital

Exclusion criteria

• Pre-existing respiratory failure,renal failure,hepatic encephalopathy

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups, including a placebo group

Dexmedetomidine Group

Experimental group

Description:

Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.

Treatment:

Drug: Dexmedetomidine

Normal saline Group

Placebo Comparator group

Description:

Equal volume normal saline substitute for dexmedetomidine

Treatment:

Drug: Normal saline